All CYPRESS Study Articles
-
258Latest Myopia NewsSightGlass Vision Shares 24-Month Data on DOT Spectacles at ARVO 2026
May 6, 2026 DALLAS — SightGlass Vision shared the latest 24-month clinical data for its DOT spectacles at the Association for Research in...
-
900ClinicalA New Vision for Myopia Management: The Canadian Launch of MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™
March 16, 2026 On July 1, 2025, the city of Halifax served as the backdrop for a significant milestone in pediatric eye...
-
1.3KLatest Myopia NewsSightGlass Vision Shares Latest DOT Spectacle Findings at ARVO 2025
May 5, 2025 DALLAS — SightGlass Vision is presenting the latest findings on its DOT spectacles at the 2025 Association for Research...
-
1.8KLatest Myopia NewsSightGlass’ DOT Spectacle Lenses Receive FDA Breakthrough Device Designation
February 14, 2024 LOS ALTOS, Calif. — SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses have received Breakthrough Device designation from the...
-
1.7KLatest Myopia NewsSightGlass Vision Releases First White Paper on DOT Lenses
September 20, 2023 LOS ALTOS, Calif. — SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses are the subject of a recently released...
-
2.2KLatest Myopia NewsMyopia Research Highlights from the ARVO 2023 Meeting
May 3, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE A gold mine for cutting-edge myopia research, the ARVO Meeting, held...
-
3.0KLatest Myopia NewsCooperVision Announces Results from Two-Year SightGlass Clinical Trial
October 7, 2021 SAN RAMON, Calif. — CooperVision announced the results from its two-year clinical trial on the SightGlass Diffusion Optics Technology§...